Secondary malignancies in pediatric cancer survivors: Perspectives and review of the literature

International Journal of Cancer

Volumn 135, Issue 8, 2014, Pages 1764-1773

  Choi, Daniel K ^a   Helenowski, Irene ^b   Hijiya, Nobuko ^a,b  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

childhood cancer survivor; long term morbidities; secondary malignancy

Indexed keywords

ALKYLATING AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GYRASE INHIBITOR; IFOSFAMIDE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER REGISTRY; CANCER RISK; CANCER SURVIVOR; CHILD; CHILDHOOD CANCER; CRANIOSPINAL IRRADIATION; CYTOGENETICS; DISEASE SURVEILLANCE; EWING SARCOMA; GENETIC PREDISPOSITION; GERMLINE MUTATION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSITY MODULATED RADIATION THERAPY; IONIZING RADIATION; LYMPHOPROLIFERATIVE DISEASE; MOLECULAR GENETICS; OUTCOME ASSESSMENT; PATIENT COUNSELING; PRIORITY JOURNAL; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SECOND CANCER; SOLID TUMOR;

CHILDHOOD CANCER SURVIVOR; LONG-TERM MORBIDITIES; SECONDARY MALIGNANCY;

ANTINEOPLASTIC AGENTS; EARLY DETECTION OF CANCER; GENES, NEOPLASM; HUMANS; MUTATION; NEOPLASMS, SECOND PRIMARY; RISK FACTORS; SURVIVORS;

EID: 84905720860     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28991     Document Type: Article

References (77)

1. SEER Cancer Statistics Review 1975-2010. 2013; http://seer.cancer.gov/ csr/1975-2010/browse-csr.php?section=28&page=sect-28-table.08.html. Accessed 10/1/2013.
2. National Cancer Institute. Late Effects of Treatment for Childhood Cancer: Subsequent Neoplasms. 2013; http://www.cancer.gov/cancertopics/pdq/ treatment/lateeffects/HealthProfessional/page2#Reference2.18. Accessed 10/1/2013.
3. Friedman DL, Whitton J, Leisenring W, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2010; 102: 1083-95.
4. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat. Research Data (1973-2010), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission. 2013.
5. Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2008; 100: 1368-79.
6. Thirman MJ, Larson RA,. Therapy-related myeloid leukemia. Hematol Oncol Clin North America 1996; 10: 293-320.
7. Hijiya N, Ness KK, Ribeiro RC, Hudson MM,. Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues. Cancer 2009; 115: 23-35.
8. Davies SM,. Therapy-related leukemia associated with alkylating agents. Med Pediatr Oncol 2001; 36: 536-40.
9. Grier H, Krailo M, Link M, et al. Improved outcome in non-metastatic Ewing sarcoma and PNET of bone with the addition of ifosfamide and etoposide to vincristine, adriamycin, cyclophosphamide, and actinomycin: a Children's Cancer Group and Pediatric Oncology Group report. Proc Am Soc Clin Oncol 1994; 13: 421.
10. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. New Engl J Med 2003; 348: 694-701.
11. Bhatia S, Krailo MD, Chen Z, et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. Blood 2007; 109: 46-51.
12. Kushner BH, Zauber A, Tan CT,. Second malignancies after childhood Hodgkin's disease. The Memorial Sloan-Kettering Cancer Center experience. Cancer 1988; 62: 1364-70.
13. Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol 2011; 29: 4096-104.
14. Kenney LB, Cohen LE, Shnorhavorian M, et al. Male reproductive health after childhood, adolescent, and young adult cancers: a report from the Children's Oncology Group. J Clin Oncol 2012; 30: 3408-16.
15. Metzger ML, Meacham LR, Patterson B, et al. Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications. J Clin Oncol 2013; 31: 1239-47.
16. Fu D, Calvo JA, Samson LD,. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer 2012; 12: 104-20.
17. Kelley MR,. DNA repair inhibitors: where do we go from here? DNA Repair 2011; 10: 1183-5.
18. Ratain MJ, Kaminer LS, Bitran JD, et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 1987; 70: 1412-7.
19. Hijiya N, Hudson MM, Lensing S, et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA 2007; 297: 1207-15.
20. Felix CA,. Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol 2001; 36: 525-35.
21. Pedersen-Bjergaard J, Philip P,. Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood 1991; 78: 1147-8.
22. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991; 325: 1682-7.
23. Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999; 17: 569-77.
24. Chen CL, Fuscoe JC, Liu Q, et al. Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide. J Natl Cancer Inst 1996; 88: 1840-7.
25. Le Deley MC, Leblanc T, Shamsaldin A, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 2003; 21: 1074-81.
26. Goldsby R, Burke C, Nagarajan R, et al. Second solid malignancies among children, adolescents, and young adults diagnosed with malignant bone tumors after 1976: follow-up of a Children's Oncology Group cohort. Cancer 2008; 113: 2597-604.
27. Naoe T, Takeyama K, Yokozawa T, et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 2000; 6: 4091-95.
28. Travis LB, Ng AK, Allan JM, et al. Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst 2012; 104: 357-70.
29. Kaatsch P, Reinisch I, Spix C, et al. Case-control study on the therapy of childhood cancer and the occurrence of second malignant neoplasms in Germany. Cancer Causes Control 2009; 20: 965-80.
30. Constine LS, Tarbell N, Hudson MM, et al. Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. Int J Rad Oncol Biol Phys 2008; 72: 24-33.
31. Metayer C, Lynch CF, Clarke EA, et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol 2000; 18: 2435-43.
32. Kuttesch JF, Jr, Wexler LH, Marcus RB, et al. Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol 1996; 14: 2818-25.
33. Henderson TO, Rajaraman P, Stovall M, et al. Risk factors associated with secondary sarcomas in childhood cancer survivors: a report from the childhood cancer survivor study. Int J Radiat Oncol Biol Phys 2012; 84: 224-30.
34. Armstrong GT, Liu W, Leisenring W, et al. Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol 2011; 29: 3056-64.
35. Bhatia S, Davies SM, Scott Baker K, et al. NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: etiology and pathogenesis of late effects after HCT performed in childhood-methodologic challenges. Biol Blood Marrow Transplant 2011; 17: 1428-35.
36. Majhail NS, Brazauskas R, Rizzo JD, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 2011; 117: 316-22.
37. Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003; 101: 2015-23.
38. Curtis RE, Metayer C, Rizzo JD, et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 2005; 105: 3802-11.
39. Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 4992-5001.
40. Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29: 2230-9.
41. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360: 2730-41.
42. Packer RJ, Zhou T, Holmes E, et al. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. Neurooncology 2013; 15: 97-103.
43. Kleinerman RA, Yu CL, Little MP, et al. Variation of second cancer risk by family history of retinoblastoma among long-term survivors. J Clin Oncol 2012; 30: 950-7.
44. Fletcher O, Easton D, Anderson K, et al. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 2004; 96: 357-63.
45. Travis LB, Rabkin CS, Brown LM, et al. Cancer survivorship-genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006; 98: 15-25.
46. Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 2006; 24: 2570-5.
47. Evans DG, Birch JM, Ramsden RT, et al. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet 2006; 43: 289-94.
48. Ruijs MW, Verhoef S, Rookus MA, et al. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 2010; 47: 421-8.
49. Hisada M, Garber JE, Fung CY, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998; 90: 606-11.
50. Monsalve J, Kapur J, Malkin D, et al. Imaging of cancer predisposition syndromes in children. Radiographics 2011; 31: 263-80.
51. Foulkes WD, Bahubeshi A, Hamel N, et al. Extending the phenotypes associated with DICER1 mutations. Human Mutat 2011; 32: 1381-4.
52. Schultz KA, Pacheco MC, Yang J, et al. Ovarian sex cord-stromal tumors, pleuropulmonary blastoma and DICER1 mutations: a report from the International Pleuropulmonary Blastoma Registry. Gynecol Oncol 2011; 122: 246-50.
53. Newhauser WD, Durante M,. Assessing the risk of second malignancies after modern radiotherapy. Nat Rev Cancer 2011; 11: 438-48.
54. Paganetti H, Athar BS, Moteabbed M, et al. Assessment of radiation-induced second cancer risks in proton therapy and IMRT for organs inside the primary radiation field. Phys Med Biol 2012; 57: 6047-61.
55. Baker KS, DeFor TE, Burns LJ, et al. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352-8.
56. Satwani P, Morris E, Bradley MB, et al. Reduced intensity and non-myeloablative allogeneic stem cell transplantation in children and adolescents with malignant and non-malignant diseases. Pediatr Blood Cancer 2008; 50: 1-8.
57. Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 1175-83.
58. Gross TG, Steinbuch M, DeFor T, et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999; 23: 251-8.
59. Juvonen E, Aalto SM, Tarkkanen J, et al. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment. Bone Marrow Transplant 2003; 32: 97-102.
60. Nottage K, Lanctot J, Li Z, et al. Long-term risk for subsequent leukemia after treatment for childhood cancer: a report from the Childhood Cancer Survivor Study. Blood 2011; 117: 6315-8.
61. Brosh R, Rotter V,. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9: 701-13.
62. Olivier M, Hollstein M, Hainaut P,. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010; 2: a001008.
63. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009; 27: 1250-6.
64. Chintagumpala M, Chevez-Barrios P, Paysse EA, et al. Retinoblastoma: review of current management. Oncologist 2007; 12: 1237-46.
65. Rushlow D, Piovesan B, Zhang K, et al. Detection of mosaic RB1 mutations in families with retinoblastoma. Hum Mutat 2009; 30: 842-51.
66. Marees T, Moll AC, Imhof SM, et al. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 2008; 100: 1771-9.
67. Children's Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. 2008; www. survivorshipguidelines.org, October 1, 2013.
68. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004; 22: 4979-90.
69. Scottish Collegiate Guidelines Network. Long term follow up of survivors of childhood cancer. 2013; http://www.sign.ac.uk/pdf/sign132.pdf. Accessed October 1, 2013.
70. American Cancer Society. Childhood Cancer: Late Effects of Cancer Treatment. 2012; http://www.cancer.org/acs/groups/cid/documents/webcontent/ 002043-pdf.pdf. Accessed October 1, 2013.
71. Smith RA, Brooks D, Cokkinides V, et al. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin 2013; 63: 88-105.
72. United Kingdom Children's Cancer Study Group LEG. Therapy Based Long Term Follow Up, 2nd edn. April 2005; http://www.cclg.org.uk/dynamic-files/LTFU-full. pdf. Accessed October 1, 2013.
73. Nathan PC, Greenberg ML, Ness KK, et al. Medical care in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol 2008; 26: 4401-9.
74. Nathan PC, Ness KK, Mahoney MC, et al. Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: a report from the childhood cancer survivor study. Ann Intern Med 2010; 153: 442-51.
75. Mulder R, Kremer L, Hudson M, et al. Recommendations for Breast Cancer Surveillance for Female Childhood, Adolescent and Young Adult Cancer Survivors Treated with Chest Radiation: a report from the international late effects of childhood cancer guideline harmonization group. Lancet Oncol, in press.
76. Perkins JL, Liu Y, Mitby PA, et al. Nonmelanoma skin cancer in survivors of childhood and adolescent cancer: a report from the childhood cancer survivor study. J Clin Oncol 2005; 23: 3733-41.
77. Freyer DR,. Transition of care for young adult survivors of childhood and adolescent cancer: rationale and approaches. J Clin Oncol 2010; 28: 4810-18.